Deals, Trends, and Predictions
Taking the pulse of healthcare's premier conference
Healthcare’s premier industry event returned to a rainy San Francisco on January 9-12, 2022. The J.P. Morgan Healthcare conference has expanded beyond its roots as a life-sciences focused, sell-side event into a sprawling dealmaking and networking week for most of the major VC, PE, and strategic players across the healthcare industry.
In our latest analyst note, PitchBook analysts Rebecca Springer and Aaron DeGagne share insights on key announcements, themes, and predictions from both company presentations and conference chatter.
Key takeaways
Given macroeconomic conditions, the outlook among attendees for 2023 deal activity was mixed. Buyer-seller price expectation mismatches are a key impediment to middle market PE deals. Corporate VC arms are still active at the late stage.
Element Biosciences announced a $200 genome as lower sequencing costs promise to accelerate innovation in genome-based research and diagnostics. Novel gene editing applications were also in the spotlight.
Chess pieces keep moving in the primary care game. CVS’ reported play to acquire One Medical for more than $10 billion would create a powerful rival to Humana’s CenterWell and Conviva Care Center and constitute a defensive play against Walmart.